Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 4 | 2024 | 352 | 1.970 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 128 | 1.580 |
Why?
|
| Ovarian Neoplasms | 3 | 2024 | 312 | 1.470 |
Why?
|
| Genital Neoplasms, Female | 3 | 2021 | 11 | 1.150 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2017 | 35 | 1.150 |
Why?
|
| Uterine Neoplasms | 2 | 2017 | 39 | 1.100 |
Why?
|
| Surgical Wound Infection | 1 | 2024 | 16 | 0.960 |
Why?
|
| Endometrial Neoplasms | 4 | 2021 | 66 | 0.950 |
Why?
|
| Carcinoma, Endometrioid | 3 | 2021 | 18 | 0.860 |
Why?
|
| Infertility | 1 | 2022 | 18 | 0.820 |
Why?
|
| Aged | 24 | 2024 | 6741 | 0.750 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 17 | 0.740 |
Why?
|
| Community-Based Participatory Research | 6 | 2024 | 317 | 0.690 |
Why?
|
| Residence Characteristics | 3 | 2018 | 322 | 0.690 |
Why?
|
| Community Health Services | 4 | 2017 | 185 | 0.690 |
Why?
|
| Middle Aged | 28 | 2024 | 10129 | 0.690 |
Why?
|
| Violence | 2 | 2018 | 134 | 0.670 |
Why?
|
| Female | 35 | 2024 | 20969 | 0.670 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 182 | 0.650 |
Why?
|
| Humans | 51 | 2024 | 37093 | 0.650 |
Why?
|
| Poverty | 3 | 2016 | 348 | 0.600 |
Why?
|
| Neoplasm Staging | 7 | 2022 | 275 | 0.580 |
Why?
|
| Retrospective Studies | 7 | 2024 | 2026 | 0.580 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2019 | 169 | 0.550 |
Why?
|
| Community-Institutional Relations | 3 | 2017 | 187 | 0.550 |
Why?
|
| Medically Uninsured | 2 | 2016 | 56 | 0.540 |
Why?
|
| Cohort Studies | 5 | 2024 | 1492 | 0.490 |
Why?
|
| Albuminuria | 2 | 2012 | 76 | 0.480 |
Why?
|
| Myometrium | 1 | 2014 | 13 | 0.480 |
Why?
|
| Urban Health Services | 1 | 2014 | 37 | 0.460 |
Why?
|
| Lymph Nodes | 1 | 2014 | 67 | 0.460 |
Why?
|
| Multilingualism | 1 | 2014 | 46 | 0.460 |
Why?
|
| Neoplasms | 5 | 2015 | 1103 | 0.450 |
Why?
|
| Adult | 23 | 2024 | 11712 | 0.440 |
Why?
|
| Breast Neoplasms | 4 | 2015 | 1502 | 0.430 |
Why?
|
| Cooperative Behavior | 3 | 2014 | 219 | 0.430 |
Why?
|
| SEER Program | 3 | 2017 | 91 | 0.400 |
Why?
|
| Los Angeles | 9 | 2023 | 380 | 0.390 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2015 | 864 | 0.370 |
Why?
|
| Survival Rate | 4 | 2021 | 311 | 0.370 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 233 | 0.360 |
Why?
|
| Health Status Disparities | 4 | 2015 | 642 | 0.350 |
Why?
|
| Mass Screening | 1 | 2012 | 462 | 0.330 |
Why?
|
| Organizational Case Studies | 1 | 2008 | 29 | 0.320 |
Why?
|
| Quality of Health Care | 1 | 2008 | 138 | 0.290 |
Why?
|
| Patient Care Management | 1 | 2006 | 6 | 0.290 |
Why?
|
| Social Welfare | 1 | 2006 | 29 | 0.280 |
Why?
|
| Models, Cardiovascular | 1 | 2007 | 49 | 0.280 |
Why?
|
| Interdisciplinary Communication | 1 | 2006 | 36 | 0.280 |
Why?
|
| Male | 24 | 2020 | 20025 | 0.280 |
Why?
|
| Long-Term Care | 2 | 2022 | 42 | 0.270 |
Why?
|
| Early Detection of Cancer | 3 | 2020 | 336 | 0.270 |
Why?
|
| Prognosis | 6 | 2022 | 739 | 0.250 |
Why?
|
| Health Education | 1 | 2008 | 338 | 0.250 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2024 | 7 | 0.240 |
Why?
|
| Young Adult | 8 | 2020 | 4268 | 0.240 |
Why?
|
| Clinical Medicine | 1 | 2004 | 4 | 0.240 |
Why?
|
| Medicaid | 2 | 2007 | 109 | 0.240 |
Why?
|
| Health Services | 1 | 2004 | 57 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 2 | 2020 | 13 | 0.230 |
Why?
|
| Health Services Research | 1 | 2004 | 148 | 0.220 |
Why?
|
| Risk Assessment | 5 | 2021 | 753 | 0.220 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 441 | 0.210 |
Why?
|
| Lymphatic Metastasis | 3 | 2022 | 65 | 0.210 |
Why?
|
| Alopecia | 1 | 2022 | 9 | 0.210 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 2721 | 0.210 |
Why?
|
| Adolescent | 9 | 2020 | 5363 | 0.210 |
Why?
|
| Disinfection | 1 | 2022 | 9 | 0.210 |
Why?
|
| Infection Control | 1 | 2022 | 14 | 0.210 |
Why?
|
| Cross Infection | 1 | 2022 | 38 | 0.200 |
Why?
|
| Insurance Coverage | 2 | 2016 | 100 | 0.200 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 485 | 0.200 |
Why?
|
| Vaccines | 1 | 2022 | 55 | 0.190 |
Why?
|
| Cardiovascular Diseases | 2 | 2007 | 664 | 0.190 |
Why?
|
| Incidence | 2 | 2022 | 922 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2017 | 2379 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 37 | 0.190 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 18 | 0.190 |
Why?
|
| DNA Mismatch Repair | 1 | 2020 | 25 | 0.180 |
Why?
|
| Drug Interactions | 1 | 2021 | 141 | 0.180 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 54 | 0.180 |
Why?
|
| Models, Statistical | 1 | 2021 | 180 | 0.180 |
Why?
|
| Cisplatin | 1 | 2020 | 72 | 0.180 |
Why?
|
| Comprehensive Health Care | 1 | 2019 | 10 | 0.180 |
Why?
|
| Medical Record Linkage | 1 | 2019 | 16 | 0.180 |
Why?
|
| Postoperative Complications | 1 | 2021 | 210 | 0.180 |
Why?
|
| United States | 6 | 2019 | 4223 | 0.170 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2019 | 7 | 0.170 |
Why?
|
| Health Personnel | 1 | 2022 | 228 | 0.170 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 974 | 0.170 |
Why?
|
| Antibodies, Protozoan | 1 | 2020 | 79 | 0.170 |
Why?
|
| Telemedicine | 1 | 2023 | 182 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 643 | 0.170 |
Why?
|
| Electronic Health Records | 1 | 2019 | 66 | 0.170 |
Why?
|
| Chagas Disease | 1 | 2020 | 98 | 0.170 |
Why?
|
| Midwestern United States | 1 | 2018 | 19 | 0.160 |
Why?
|
| Patient Selection | 2 | 2021 | 164 | 0.160 |
Why?
|
| Developing Countries | 2 | 2009 | 99 | 0.160 |
Why?
|
| Risk | 2 | 2021 | 267 | 0.160 |
Why?
|
| Mental Disorders | 1 | 2022 | 309 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2019 | 277 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 2 | 2020 | 251 | 0.150 |
Why?
|
| Allostasis | 1 | 2017 | 12 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 198 | 0.150 |
Why?
|
| Sex Factors | 2 | 2018 | 898 | 0.140 |
Why?
|
| Pregnancy | 1 | 2022 | 1549 | 0.140 |
Why?
|
| Qualitative Research | 2 | 2017 | 446 | 0.140 |
Why?
|
| Religion | 1 | 2017 | 87 | 0.140 |
Why?
|
| Social Class | 2 | 2016 | 247 | 0.140 |
Why?
|
| Chicago | 1 | 2016 | 30 | 0.140 |
Why?
|
| Perception | 2 | 2015 | 195 | 0.130 |
Why?
|
| Mortality | 1 | 2017 | 145 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 140 | 0.130 |
Why?
|
| Research Subjects | 1 | 2015 | 32 | 0.130 |
Why?
|
| Healthcare Disparities | 3 | 2015 | 494 | 0.120 |
Why?
|
| Pitch Discrimination | 1 | 2014 | 2 | 0.120 |
Why?
|
| Voice | 1 | 2014 | 4 | 0.120 |
Why?
|
| Delphi Technique | 1 | 2014 | 23 | 0.120 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 31 | 0.120 |
Why?
|
| Health Behavior | 3 | 2015 | 537 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 204 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2014 | 77 | 0.120 |
Why?
|
| Trust | 1 | 2015 | 133 | 0.120 |
Why?
|
| Risk Factors | 5 | 2020 | 3562 | 0.110 |
Why?
|
| Models, Neurological | 1 | 2014 | 128 | 0.110 |
Why?
|
| Language | 1 | 2014 | 157 | 0.110 |
Why?
|
| HIV Infections | 1 | 2006 | 2303 | 0.110 |
Why?
|
| Program Development | 1 | 2014 | 233 | 0.110 |
Why?
|
| Registries | 3 | 2020 | 335 | 0.110 |
Why?
|
| Health Status | 1 | 2016 | 380 | 0.110 |
Why?
|
| Age Factors | 4 | 2020 | 1033 | 0.100 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 290 | 0.100 |
Why?
|
| Chronic Disease | 3 | 2016 | 484 | 0.100 |
Why?
|
| Nutrition Assessment | 1 | 2012 | 79 | 0.100 |
Why?
|
| Time Factors | 1 | 2016 | 1742 | 0.100 |
Why?
|
| Acupuncture Therapy | 1 | 2011 | 12 | 0.100 |
Why?
|
| Health Promotion | 1 | 2017 | 653 | 0.090 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2010 | 14 | 0.090 |
Why?
|
| Fatigue | 1 | 2011 | 83 | 0.090 |
Why?
|
| Internet | 1 | 2012 | 211 | 0.090 |
Why?
|
| Feeding Behavior | 2 | 2012 | 454 | 0.090 |
Why?
|
| Hypertension | 3 | 2019 | 796 | 0.090 |
Why?
|
| Universities | 1 | 2014 | 442 | 0.090 |
Why?
|
| Quality of Life | 1 | 2014 | 481 | 0.090 |
Why?
|
| Self Care | 1 | 2011 | 159 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 215 | 0.090 |
Why?
|
| Snake Bites | 1 | 2009 | 1 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2014 | 400 | 0.080 |
Why?
|
| Zoonoses | 1 | 2009 | 17 | 0.080 |
Why?
|
| Leptospirosis | 1 | 2009 | 25 | 0.080 |
Why?
|
| Case Management | 1 | 2008 | 20 | 0.080 |
Why?
|
| Creatinine | 1 | 2008 | 103 | 0.080 |
Why?
|
| Consensus | 1 | 2008 | 45 | 0.080 |
Why?
|
| Health Surveys | 2 | 2008 | 373 | 0.080 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 1067 | 0.080 |
Why?
|
| Education | 1 | 2008 | 55 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2014 | 583 | 0.080 |
Why?
|
| Food Supply | 1 | 2008 | 112 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2021 | 208 | 0.070 |
Why?
|
| Insurance, Health | 1 | 2007 | 126 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 215 | 0.060 |
Why?
|
| Capital Financing | 1 | 2004 | 2 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 268 | 0.060 |
Why?
|
| Cadherins | 1 | 2005 | 90 | 0.060 |
Why?
|
| Body Mass Index | 3 | 2015 | 854 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2004 | 29 | 0.060 |
Why?
|
| Internal Medicine | 1 | 2004 | 24 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 284 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2005 | 166 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2004 | 32 | 0.060 |
Why?
|
| Prevalence | 3 | 2019 | 1455 | 0.060 |
Why?
|
| Public Health | 1 | 2008 | 372 | 0.060 |
Why?
|
| Teaching | 1 | 2004 | 55 | 0.060 |
Why?
|
| Forecasting | 1 | 2004 | 128 | 0.060 |
Why?
|
| Child | 2 | 2022 | 3131 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2005 | 195 | 0.050 |
Why?
|
| San Francisco | 1 | 2022 | 32 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 13 | 0.050 |
Why?
|
| Patients' Rooms | 1 | 2022 | 1 | 0.050 |
Why?
|
| Fomites | 1 | 2022 | 2 | 0.050 |
Why?
|
| Disinfectants | 1 | 2022 | 7 | 0.050 |
Why?
|
| Health Facilities | 1 | 2022 | 27 | 0.050 |
Why?
|
| New York | 1 | 2022 | 71 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2022 | 117 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 935 | 0.050 |
Why?
|
| Risk-Taking | 2 | 2015 | 451 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 196 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2020 | 28 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2021 | 291 | 0.050 |
Why?
|
| Bolivia | 1 | 2020 | 9 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2022 | 301 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2020 | 47 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 288 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 68 | 0.040 |
Why?
|
| Endometrium | 1 | 2020 | 60 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 22 | 0.040 |
Why?
|
| Gynecology | 1 | 2019 | 31 | 0.040 |
Why?
|
| Causality | 2 | 2009 | 44 | 0.040 |
Why?
|
| Brazil | 2 | 2009 | 64 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 610 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 303 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 448 | 0.040 |
Why?
|
| Trypanosoma cruzi | 1 | 2020 | 149 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 935 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 515 | 0.040 |
Why?
|
| Rural Population | 1 | 2020 | 294 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2020 | 325 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 601 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 97 | 0.040 |
Why?
|
| Infant | 1 | 2020 | 1046 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 156 | 0.030 |
Why?
|
| Comorbidity | 2 | 2009 | 623 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 1378 | 0.030 |
Why?
|
| Environment Design | 1 | 2016 | 24 | 0.030 |
Why?
|
| Community Health Centers | 1 | 2016 | 45 | 0.030 |
Why?
|
| Mutation | 1 | 2020 | 1095 | 0.030 |
Why?
|
| Marketing of Health Services | 1 | 2015 | 7 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1418 | 0.030 |
Why?
|
| Diet | 2 | 2012 | 801 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 59 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2009 | 1369 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2015 | 117 | 0.030 |
Why?
|
| Pitch Perception | 1 | 2014 | 2 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2014 | 21 | 0.030 |
Why?
|
| Motor Cortex | 1 | 2014 | 22 | 0.030 |
Why?
|
| Algorithms | 1 | 2017 | 465 | 0.030 |
Why?
|
| Nerve Net | 1 | 2014 | 76 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2014 | 112 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2014 | 137 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 54 | 0.030 |
Why?
|
| Relaxation Therapy | 1 | 2011 | 4 | 0.030 |
Why?
|
| Integrative Medicine | 1 | 2011 | 5 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 2011 | 54 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2011 | 115 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 481 | 0.020 |
Why?
|
| Castration | 1 | 2010 | 34 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2012 | 212 | 0.020 |
Why?
|
| Austria | 1 | 2010 | 4 | 0.020 |
Why?
|
| Focus Groups | 1 | 2012 | 348 | 0.020 |
Why?
|
| Physicians | 1 | 2012 | 163 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 441 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 661 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2011 | 233 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 219 | 0.020 |
Why?
|
| Bothrops | 1 | 2009 | 1 | 0.020 |
Why?
|
| Antivenins | 1 | 2009 | 2 | 0.020 |
Why?
|
| Crotalus | 1 | 2009 | 2 | 0.020 |
Why?
|
| Penicillins | 1 | 2009 | 12 | 0.020 |
Why?
|
| Doxycycline | 1 | 2009 | 30 | 0.020 |
Why?
|
| Rodentia | 1 | 2009 | 43 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 381 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2009 | 45 | 0.020 |
Why?
|
| Social Support | 1 | 2011 | 394 | 0.020 |
Why?
|
| Urban Health | 1 | 2009 | 95 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2008 | 41 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 75 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 191 | 0.020 |
Why?
|
| Drug Costs | 1 | 2007 | 28 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 455 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 212 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2007 | 242 | 0.020 |
Why?
|
| Exercise | 1 | 2011 | 613 | 0.020 |
Why?
|
| Medicare | 1 | 2007 | 195 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2007 | 534 | 0.020 |
Why?
|
| Carbohydrate Dehydrogenases | 1 | 2005 | 14 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 583 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2006 | 167 | 0.010 |
Why?
|
| Mexico | 1 | 2005 | 240 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 325 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 893 | 0.010 |
Why?
|
| Animals | 2 | 2009 | 15081 | 0.010 |
Why?
|